Abstract
Epicardial adipose tissue surrounds and infiltrates the heart. Epicardial fat displays unique anatomic, genetic, and biomolecular properties. People with obesity and in particular, those with abdominal obesity and associated type 2 diabetes mellitus, have an increased amount of epicardial adipose tissue (EAT). Epicardial fat works well as therapeutic target due to its fast-responding metabolism, organ fat specificity, and easy measurability. Epicardial fat responds to thiazolidinediones (TZD), glucagon-like peptide 1-receptor agonists (GLP1A), sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP4i), and statins. Modulating epicardial fat morphology and genetic profile with targeted pharmacological agents suggests novel strategies in the pharmacotherapy of diabetes and obesity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alexopoulos N et al (2013) Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (beyond endorsed lipid lowering with EBT scanning). J Am Coll Cardiol 61(19):1956–1961. https://doi.org/10.1016/j.jacc.2012.12.051
Aroor A et al (2013) DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes. Cardiorenal Med 3(1):48–56. https://doi.org/10.1159/000348756
Aslanabadi N et al (2014) Epicardial and pericardial fat volume correlate with the severity of coronary artery stenosis. J Cardiovasc Thorac Res 6(4):235–239. https://doi.org/10.15171/jcvtr.2014.018
Beiroa D et al (2014) GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 63(10):3346–3358. https://doi.org/10.2337/db14-0302
Bolinder J et al (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97(3):1020–1031. https://doi.org/10.1210/jc.2011-2260
Bouchi R et al (2017) Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol 16(1):32. https://doi.org/10.1186/s12933-017-0516-8
Boudina S, Abel ED (2010) Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11(1):31–39. https://doi.org/10.1007/s11154-010-9131-7
Camarena V et al (2017) Novel atherogenic pathways from the differential transcriptome analysis of diabetic epicardial adipose tissue. Nutr Metab Cardiovasc Dis 27:739–750. https://doi.org/10.1016/j.numecd.2017.05.010
Christensen RH, von Scholten BJ et al (2019a) Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. Cardiovasc Diabetol 18(1):114. https://doi.org/10.1186/s12933-019-0917-y
Christensen RH, Hansen CS et al (2019b) Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. Diabetes Obes Metab 21(8):2006–2011. https://doi.org/10.1111/dom.13758
Dallongeville J et al (2012) Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. Eur J Prev Cardiol 19(2):241–249. https://doi.org/10.1177/1741826710394305
DÃaz-RodrÃguez E et al (2018) Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res 114(2):336–346. https://doi.org/10.1093/cvr/cvx186
Distel E et al (2012) Early induction of a brown-like phenotype by rosiglitazone in the epicardial adipose tissue of fatty Zucker rats. Biochimie 94(8):1660–1667. https://doi.org/10.1016/j.biochi.2012.04.014
Dozio E et al (2019) Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk? Int J Cardiol 292:218–224. https://doi.org/10.1016/j.ijcard.2019.04.039
Dutour A et al (2016) Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 18(9):882–891. https://doi.org/10.1111/dom.12680
Elisha B et al (2016) Body composition and epicardial fat in type 2 diabetes patients following insulin detemir versus insulin glargine initiation. Horm Metab Res 48(1):42–47. https://doi.org/10.1055/s-0035-1554688
Flegal KM et al (2005) Excess deaths associated with underweight, overweight, and obesity. JAMA 293(15):1861–1867. https://doi.org/10.1001/jama.293.15.1861
Fox CS et al (2007) Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116(1):39–48. https://doi.org/10.1161/CIRCULATIONAHA.106.675355
Fukuda T et al (2017) Ipragliflozin reduces Epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther Res Treat Educ Diabetes Relat Disord 8(4):851–861. https://doi.org/10.1007/s13300-017-0279-y
Gerstein HC et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
Greulich S et al (2012) Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction. Circulation 126(19):2324–2334. https://doi.org/10.1161/CIRCULATIONAHA.111.039586
Grosso AF et al (2014) Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetol Metab Syndr 6(1):47. https://doi.org/10.1186/1758-5996-6-47
Grundy SM et al (2005) Diagnosis and management of the metabolic syndrome. Circulation 112(17):2735–2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
Guedes EP et al (2013) Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetol Metab Syndr 5(1):25. https://doi.org/10.1186/1758-5996-5-25
Henrichot E et al (2005) Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol 25(12):2594–2599. https://doi.org/10.1161/01.ATV.0000188508.40052.35
Hiuge-Shimizu A et al (2012) Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Ann Med 44(1):82–92. https://doi.org/10.3109/07853890.2010.526138
Iacobellis G (2015) Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol 11(6):363–371. https://doi.org/10.1038/nrendo.2015.58
Iacobellis G, Mahabadi AA (2019) Is epicardial fat attenuation a novel marker of coronary inflammation? Atherosclerosis 284:212–213. https://doi.org/10.1016/j.atherosclerosis.2019.02.023
Iacobellis G, Villasante Fricke AC (2020) Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity. J Endocr Soc 4(4):bvz042. https://doi.org/10.1210/jendso/bvz042
Iacobellis G, Willens HJ (2009) Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 22(12):1311–1319; quiz 1417–8. https://doi.org/10.1016/j.echo.2009.10.013
Iacobellis G, Ribaudo MC et al (2003a) Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 88(11):5163–5168. https://doi.org/10.1210/jc.2003-030698
Iacobellis G, Assael F et al (2003b) Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 11(2):304–310. https://doi.org/10.1038/oby.2003.45
Iacobellis G, Corradi D, Sharma AM (2005) Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2(10):536–543. https://doi.org/10.1038/ncpcardio0319
Iacobellis G, Sharma AM et al (2007a) Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res 5(2):275–279. https://doi.org/10.2174/157016207780077084
Iacobellis G, Pellicelli AM et al (2007b) Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Cardiol 99(10):1470–1472. https://doi.org/10.1016/j.amjcard.2006.12.082
Iacobellis G, Malavazos AE, Corsi MM (2011) Epicardial fat: from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol 43(12):1651–1654. https://doi.org/10.1016/j.biocel.2011.09.006
Iacobellis G, Camarena V et al (2017a) Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes. Horm Metab Res 49(8):625–630. https://doi.org/10.1055/s-0043-109563
Iacobellis G, Mohseni M et al (2017b) Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring) 25(2):311–316. https://doi.org/10.1002/oby.21718
Iacobellis G, Gra-Menendez S, Gra-Menendez S (2020) Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity. Obesity 28(6):1068–1074. https://doi.org/10.1002/oby.22798
Jastreboff AM et al (2019) Obesity as a disease: the obesity society 2018 position statement. Obesity (Silver Spring) 27(1):7–9. https://doi.org/10.1002/oby.22378
Jonker JT et al (2010) Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95(1):456–460. https://doi.org/10.1210/jc.2009-1441
Kim SH, Després J-P, Koh KK (2016) Obesity and cardiovascular disease: friend or foe? Eur Heart J 37(48):3560–3568. https://doi.org/10.1093/eurheartj/ehv509
Lemieux I et al (2000) Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102(2):179–184. https://doi.org/10.1161/01.cir.102.2.179
Lemieux I et al (2007) Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? Can J Cardiol 23(SUPPL. B):23B–31B. https://doi.org/10.1016/s0828-282x(07)71007-3
Levelt E et al (2016) Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J Am Coll Cardiol 68(1):53–63. https://doi.org/10.1016/j.jacc.2016.03.597
Li Y et al (2019) Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol 18(1):3. https://doi.org/10.1186/s12933-019-0807-3
Lima-MartÃnez MM et al (2016) Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine 51(3):448–455. https://doi.org/10.1007/s12020-015-0710-y
Mahaffey KW et al (2018) Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation 137(4):323–334. https://doi.org/10.1161/CIRCULATIONAHA.117.032038
Malavazos AE et al (2008) Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis 18(8):523–530. https://doi.org/10.1016/j.numecd.2007.09.001
Malavazos AE et al (2010) Relation of echocardiographic epicardial fat thickness and myocardial fat. Am J Cardiol 105(12):1831–1835. https://doi.org/10.1016/j.amjcard.2010.01.368
Malavazos AE et al (2020) Does epicardial fat contribute to COVID-19 myocardial inflammation? Eur Heart J 41(24):2333. https://doi.org/10.1093/eurheartj/ehaa471
Marso SP, Daniels GH et al (2016a) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322. https://doi.org/10.1056/NEJMoa1603827
Marso SP, Bain SC et al (2016b) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141
Mazurek T et al (2003) Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108(20):2460–2466. https://doi.org/10.1161/01.CIR.0000099542.57313.C5
Morano S et al (2015) Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Acta Diabetol 52(4):727–732. https://doi.org/10.1007/s00592-014-0710-z
Nagai H et al (2008) Abstract 710: pioglitazone treatment reduces epicardial fat in patients with type 2 diabetes mellitus and improves left ventricular diastolic function. Circulation 118(suppl_18):S_604–S_604. https://doi.org/10.1161/circ.118.suppl\_18.S\_604
Neeland IJ et al (2013) Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 21(9):E439–E447. https://doi.org/10.1002/oby.20135
Neeland IJ et al (2019) Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 7(9):715–725. https://doi.org/10.1016/S2213-8587(19)30084-1
Okorodudu DO et al (2010) Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes 34(5):791–799. https://doi.org/10.1038/ijo.2010.5
Ouchi N et al (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85–97. https://doi.org/10.1038/nri2921
Park J-H et al (2010) Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe. J Cardiovasc Ultrasound 18(4):121–126. https://doi.org/10.4250/jcu.2010.18.4.121
Pezeshkian M, Mahtabipour M-R (2013) Epicardial and subcutaneous adipose tissue fatty acids profiles in diabetic and non-diabetic patients candidate for coronary artery bypass graft. BioImpacts: BI 3(2):83–89. https://doi.org/10.5681/bi.2013.004
Pyke C, Knudsen LB (2013) The glucagon-like peptide-1 receptor--or not? Endocrinology 154(1):4–8. https://doi.org/10.1210/en.2012-2124
Rabkin SW (2014) The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis. Metab Syndr Relat Disord 12(1):31–42. https://doi.org/10.1089/met.2013.0107
Sacks HS, Fain JN (2007) Human epicardial adipose tissue: a review. Am Heart J 153(6):907–917. https://doi.org/10.1016/j.ahj.2007.03.019
Sacks HS et al (2011) Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care 34(3):730–733. https://doi.org/10.2337/dc10-2083
Saeedi P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843
Saeedi P et al (2020) Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract 162:108086. https://doi.org/10.1016/j.diabres.2020.108086
Sato T et al (2018) The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol 17(1):6. https://doi.org/10.1186/s12933-017-0658-8
Shah Z et al (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124(21):2338–2349. https://doi.org/10.1161/CIRCULATIONAHA.111.041418
Shimasaki T et al (2013) The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity. PLoS One 8(5):e63626. https://doi.org/10.1371/journal.pone.0063626
Smith U, Kahn BB (2016) Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med 280(5):465–475. https://doi.org/10.1111/joim.12540
Tchkonia T et al (2013) Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 17(5):644–656. https://doi.org/10.1016/j.cmet.2013.03.008
Vendrell J et al (2011) Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 152(11):4072–4079. https://doi.org/10.1210/en.2011-1070
Wang C-P et al (2009) Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clin Endocrinol 70(6):876–882. https://doi.org/10.1111/j.1365-2265.2008.03411.x
Wende AR, Abel ED (2010) Lipotoxicity in the heart. Biochim Biophys Acta 1801(3):311–319. https://doi.org/10.1016/j.bbalip.2009.09.023
Wiviott SD et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389
World Health Organization (2021) Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 2 Apr 2021
Yagi S et al (2017) Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 9:78. https://doi.org/10.1186/s13098-017-0275-4
Yamaguchi Y et al (2015) Adipogenesis and epicardial adipose tissue: a novel fate of the epicardium induced by mesenchymal transformation and PPARγ activation. Proc Natl Acad Sci U S A 112(7):2070–2075. https://doi.org/10.1073/pnas.1417232112
Yang J et al (2013) Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes. Int J Mol Med 31(6):1429–1435. https://doi.org/10.3892/ijmm.2013.1350
Yerramasu A et al (2012) Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis 220(1):223–230. https://doi.org/10.1016/j.atherosclerosis.2011.09.041
Zinman B et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Iacobellis, G., Basilico, S., Malavazos, A.E. (2022). Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy. In: Eckel, J., Clément, K. (eds) From Obesity to Diabetes. Handbook of Experimental Pharmacology, vol 274. Springer, Cham. https://doi.org/10.1007/164_2021_577
Download citation
DOI: https://doi.org/10.1007/164_2021_577
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-99994-0
Online ISBN: 978-3-030-99995-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)